Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of hepatitis C

J Moussalli1, P Opolon, T Poynard

  • 1Service d'Hépato-gastroentérologie, Groupe hospitalier Pitié-Salpétrière, Paris, France.

Journal of Viral Hepatitis
|May 8, 1998
PubMed
Summary

Chronic hepatitis C treatment aims for viral eradication to prevent liver disease progression. Combination therapy with Interferon-alpha (IFN-alpha) and Ribavirin shows higher sustained remission rates than IFN-alpha alone.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with "highest risk" RET mutation.

Stem cell research·2017
Same author

Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.

Stem cell research·2016
Same author

Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation.

Stem cell research·2016
Same author

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.

Cell death & disease·2014
Same author

Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Oncogene·2014
Same author

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice.

Leukemia·2014

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C is a significant global health issue, potentially leading to cirrhosis and hepatocellular carcinoma.
  • Therapeutic goals include viral eradication for long-term remission and reducing liver fibrosis progression.

Purpose of the Study:

  • To evaluate the efficacy of Interferon-alpha (IFN-alpha) and Ribavirin in treating chronic hepatitis C.
  • To determine optimal treatment regimens and assess combination therapy benefits.

Main Methods:

  • Review of Interferon-alpha (IFN-alpha) therapy, including dosage and duration.
  • Assessment of Ribavirin's efficacy, both as monotherapy and in combination with IFN-alpha.
  • Analysis of sustained remission and alanine aminotransferase (ALT) response rates.

Main Results:

  • A 12-month schedule of 3 million units (MU) IFN-alpha three times weekly achieved a sustained alanine aminotransferase (ALT) response in nearly 35% of patients.
  • Combination therapy with IFN-alpha and Ribavirin demonstrated a synergistic effect, achieving sustained remission in nearly 50% of patients.
  • Controversy remains regarding long-term benefits for transient responders and non-responders.

Conclusions:

  • Combination therapy with IFN-alpha and Ribavirin offers improved sustained remission rates for chronic hepatitis C compared to IFN-alpha alone.
  • Further research is needed to identify new drugs for improved treatment outcomes, as prolonged viral eradication is not always achieved.

Related Experiment Videos